Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study - PubMed
6 hours ago
- #Triple-Negative Breast Cancer
- #Pembrolizumab
- #Surgical Outcomes
- The study evaluated surgical outcomes after neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer (TNBC).
- Participants were randomized to receive pembrolizumab or placebo alongside chemotherapy, followed by surgery and adjuvant therapy.
- Similar proportions of participants underwent breast-conserving surgery and mastectomy in both treatment groups.
- Time from neoadjuvant treatment to surgery and from surgery to adjuvant therapy was comparable between groups.
- The only notable adverse event post-surgery was procedural pain, occurring in ≥5% of participants.
- Pathological complete nodal response was higher in the pembrolizumab group (76.7%) compared to the placebo group (69.9%).
- Adding pembrolizumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes, including type, timing, and safety.